- Home
- CSCI vs ASBP Comparison
CSCI vs ASBP Comparison
Compare CSCI & ASBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CSCI
- ASBP
- Stock Information
- Founded
- CSCI 1990
- ASBP 2021
- Country
- CSCI Canada
- ASBP United States
- Employees
- CSCI N/A
- ASBP N/A
- Industry
- CSCI
- ASBP Biotechnology: Pharmaceutical Preparations
- Sector
- CSCI
- ASBP Health Care
- Exchange
- CSCI NYSE
- ASBP Nasdaq
- Market Cap
- CSCI 10.5M
- ASBP 11.9M
- IPO Year
- CSCI 1996
- ASBP N/A
- Fundamental
- Price
- CSCI $3.61
- ASBP $0.38
- Analyst Decision
- CSCI
- ASBP
- Analyst Count
- CSCI 0
- ASBP 0
- Target Price
- CSCI N/A
- ASBP N/A
- AVG Volume (30 Days)
- CSCI 3.3K
- ASBP 36.0M
- Earning Date
- CSCI 05-13-2025
- ASBP 05-14-2025
- Dividend Yield
- CSCI N/A
- ASBP N/A
- EPS Growth
- CSCI N/A
- ASBP N/A
- EPS
- CSCI N/A
- ASBP N/A
- Revenue
- CSCI $9,030,000.00
- ASBP N/A
- Revenue This Year
- CSCI N/A
- ASBP N/A
- Revenue Next Year
- CSCI N/A
- ASBP N/A
- P/E Ratio
- CSCI N/A
- ASBP N/A
- Revenue Growth
- CSCI 36.51
- ASBP N/A
- 52 Week Low
- CSCI $1.96
- ASBP $0.22
- 52 Week High
- CSCI $7.72
- ASBP $15.80
- Technical
- Relative Strength Index (RSI)
- CSCI N/A
- ASBP N/A
- Support Level
- CSCI N/A
- ASBP N/A
- Resistance Level
- CSCI N/A
- ASBP N/A
- Average True Range (ATR)
- CSCI 0.00
- ASBP 0.00
- MACD
- CSCI 0.00
- ASBP 0.00
- Stochastic Oscillator
- CSCI 0.00
- ASBP 0.00
About CSCI COSCIENS BIOPHARMA INC
Cosciens Biopharma Inc is a biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products and active ingredients for healthcare and cosmetics industries. The company is engaged in the development of therapeutic assets and proprietary extraction technology. The Company has two reportable and operating segments: Active ingredient and Biopharmaceutical.
About ASBP Aspire Biopharma Holdings Inc. Common Stock
Aspire Biopharma Holdings Inc developing next-generation absorption of medicine that will have an impact on the opioid crisis. The group engaged in the business of developing and marketing disruptive technology for novel delivery mechanisms for do-no-harm drugs. Its nanotechnology drug formulation directly targets pain and inflammation bypassing the gastrointestinal tracts.